Use of organic compounds

Abstract

This application is directed to methods for improving glucose control by administering metformin in combination with a DPP-IV inhibitor to a patient in need thereof, in an amount sufficient to control the glucose level over an extended period of time.

1 . A method for controlling glucose levels over an extended period of time comprising administering a therapeutically effective amount of metformin or a pharmaceutically acceptable salt thereof and a DPP-IV inhibitor or a pharmaceutically acceptable salt thereof to a patient in need thereof. 
     
     
         2 . A method for controlling glycosylated hemoglobin levels over an extended period of time comprising administering a pharmaceutically effective amount of metformin or a pharmaceutically acceptable salt thereof and a DPP-IV inhibitor or a pharmaceutically acceptable salt thereof to a patient in need thereof. 
     
     
         3 . A method for monitoring the glucose level in an patient comprising treating the patient with a pharmaceutically effective amount of metformin or a pharmaceutically acceptable salt thereof in combination with a DPP-IV inhibitor or a pharmaceutically acceptable salt thereof; and checking the patients glucose level on an annual basis or once every 18 months. 
     
     
         4 . A method for monitoring the glycated haemoglobin level in an patient comprising treating the patient with a pharmaceutically effective amount of metformin or a pharmaceutically acceptable salt thereof in combination with a DPP-IV inhibitor or a pharmaceutically acceptable salt thereof; and checking the patient's glycated haemoglobin level on an annual basis or once every 18 months. 
     
     
         5 . A method for adjusting therapy in an patient treated with metformin or a pharmaceutically acceptable salt thereof in combination with a DPP-IV inhibitor or a pharmaceutically acceptable salt thereof, wherein the physician reevaluates and if necessary changes the treatment regimen in said treated patient, based on an annual progression check of patient's glucose level or glycated haemoglobin level. 
     
     
         6 . A method according to  claim 3 , wherein the glucose level progression check, the glycated haemoglobin level check or the A1C test have to be assessed by the physician only on an annual basis or once every 18 months. 
     
     
         7 . A method according to  claim 3 , wherein the progression checks of patients glucose level or glycated haemoglobin level, have to be carried out only on an annual basis or once every 18 months. 
     
     
         8 . A method according to  claim 3 , wherein the patient is reminded to perform a glucose progression check or a glycated haemoglobin level check, only on an annual basis or once every 18 months. 
     
     
         9 . The method according to  claim 1  wherein the DPP-IV inhibitor is (S)-1-[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyano-pyrrolidine in free form or in acid addition salt form. 
     
     
         10 . The method according to  claim 1  comprising administering a pharmaceutical composition comprising metformin or a pharmaceutically acceptable salt thereof and a OPP-IV inhibitor or a pharmaceutically acceptable salt thereof. 
     
     
         11 . The method according to  claim 1  wherein 50 mg of (S)-1-[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyano-pyrrolidine or a pharmaceutically acceptable salt thereof are administered daily. 
     
     
         12 . The method according to  claim 1  wherein 1500 to 2000 mg of metformin or a pharmaceutically acceptable salt thereof are administered daily. 
     
     
         13 . The method according to  claim 1  wherein the patient is suffering from a disease selected from diabetes mellitus, insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus, type A insulin resistance, IGM, IFG or IGT. 
     
     
         14 . The method according to  claim 1  wherein the patient selected is a patient whose disease was not adequately controlled by metformin alone.